Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer
Autore:
Lilleby, W; Paus, E; Skovlund, E; Fossa, SD;
Indirizzi:
Norwegian Radium Hosp, Dept Radiotherapy & Oncol, Oslo, Norway Norwegian Radium Hosp Oslo Norway pt Radiotherapy & Oncol, Oslo, Norway Norwegian Radium Hosp, Cent Lab, N-0310 Oslo, Norway Norwegian Radium Hosp Oslo Norway N-0310 , Cent Lab, N-0310 Oslo, Norway Norwegian Radium Hosp, Clin Res Off, Oslo, Norway Norwegian Radium Hosp Oslo Norway dium Hosp, Clin Res Off, Oslo, Norway
Titolo Testata:
PROSTATE
fascicolo: 2, volume: 46, anno: 2001,
pagine: 126 - 133
SICI:
0270-4137(20010201)46:2<126:PVONSM>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEURON-SPECIFIC ENOLASE; EXTERNAL-BEAM IRRADIATION; CHROMOGRANIN-A; IMMUNORADIOMETRIC ASSAY; MONOCLONAL-ANTIBODIES; RADICAL PROSTATECTOMY; CLINICAL STAGE; DIFFERENTIATION; CARCINOMA; ADENOCARCINOMA;
Keywords:
neuroendocrine serum markers; radiation treatment; prostate cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Lilleby, W Norwegian Radium Hosp, Dept Med Oncol Radiotherapy, N-0310 Oslo, Norway Norwegian Radium Hosp Oslo Norway N-0310 N-0310 Oslo, Norway
Citazione:
W. Lilleby et al., "Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer", PROSTATE, 46(2), 2001, pp. 126-133

Abstract

BACKGROUND. The prognosis of patients with localized prostate cancer depends on clinical stage, histological grade, and pretreatment prostate-specific antigen (PSA). We evaluated the additional prognostic impact of serum levels of neuron-specific enolase (NSE) and chromograninA (CgA) after curativeradiotherapy and the importance of serum PSA, analyzed 3 months after irradiation. METHODS. From 1988 to 1995, 161 patients with localized T1-4, pN0M0, prostate adenocarcinoma were treated with external radiation (66Gy, 2Gy/5 fractions per week). Frozen serum samples were assessed for CgA, NSE, and PSA before and 3 months after radiotherapy. CgA was analyzed in only 100 patients. NSE and CgA were determined by a immunometric assay. Total PSA was measured by a time-resolved fluoro-immunometric assay. RESULTS. Prior to radiotherapy CgA was elevated in 16 of 100 patients, andNSE was elevated in 33 of the 161 patients. There was no association between grade, T category or pretreatment PSA and the levels of neuroendocrine markers. Pretreatment-elevated serum NSE, but not initial CgA, identified patients with an unfavorable prognosis. A <50% reduction of PSA 3 months after radiotherapy was associated with decreased failure-fret 10 years survival. Multivariate analysis demonstrated an increased risk of failure for patients with elevated pretreatment NSE and PSA values, T3 category, and declineof PSA less than 50% 3 months after radiotherapy. The presence of none or several risk factors (1-4) defined clearly separable groups. CONCLUSION. Together with T category and pretreatment serum PSA values, serum NSE values before radiotherapy and decrease of serum PSA 3 months afterradiotherapy represent easily assessable prognostic parameters in patientsundergoing curative radiation treatment for prostate cancer. Prostate 46:126-133. 2001. (C) 2001 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 04:48:00